{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:52:09Z","timestamp":1766739129166},"reference-count":10,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.1182\/blood.2023022670","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:31:48Z","timestamp":1706805108000},"page":"379-380","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Two years later: CD19 CAR-T going the distance"],"prefix":"10.1182","volume":"143","author":[{"given":"Eli P.","family":"Darnell","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2024020116313933500_bib1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"10254","key":"2024020116313933500_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2024020116313933500_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024020116313933500_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"2024020116313933500_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024020116313933500_bib6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2024020116313933500_bib7","doi-asserted-by":"crossref","first-page":"10399","DOI":"10.1182\/blood-2022-156117","article-title":"Prophylactic corticosteroid use with axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with relapsed\/refractory large B-cell lymphoma (R\/R LBCL): 2-year follow-up of ZUMA-1 cohort 6 [abstract]","volume":"140","author":"Oluwole","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2024020116313933500_bib8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024020116313933500_bib9","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following\u00a0CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024020116313933500_bib10","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/379\/2210902\/blood_bld-2023-022670-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/379\/2210902\/blood_bld-2023-022670-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:31:54Z","timestamp":1706805114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/5\/379\/514728\/Two-years-later-CD19-CAR-T-going-the-distance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022670","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}